$RAJAF

TFA Therapeutics, Inc.

CIK:0001885680|SEC Filings

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue
Total revenue	$ 1,245,348	$ 1,253,484	$ 882,533
Total cost of revenue	484,607	347,004	116,146
Gross profit	760,741	906,480	766,387
Operating expenses
General and administrative	901,869	1,090,393	538,554
Total operating expenses	901,869	1,090,393	538,554
(Loss) income from operations	(141,128)	(183,913)	227,833
Non-operating income (expense)
Interest income (expense), net	(19,179)	(17,055)	(39,770)
Gain on disposal of fixed assets		4,328
Other income	5,485	5,339	2,752
Total non-operating expense, net	(13,694)	(7,388)	(37,018)
(Loss) income before income taxes	(154,822)	(191,301)	190,815
Income tax expense		34,957	21,530
Net (loss) income from continuing operations	(154,822)	(226,258)	169,285
Discontinued Operation
Loss from discontinued operation, net of income tax			(282,761)
Gain from sale of discontinued operation, net of income tax			865,085
Gain (loss) from discontinued operation, net of income tax			582,324
Net (loss) income	(154,822)	(226,258)	751,609
Foreign currency translation	(4,186)	2,511	47,929
Comprehensive (loss) income	$ (159,008)	$ (223,747)	$ 799,538
Earnings (loss) per common share
Continuing operations - basic (in Dollars per share)	$ 0	$ 0	$ 0
Continuing operations - diluted (in Dollars per share)	0	0	0
Discontinued operations - basic (in Dollars per share)			0.01
Discontinued operations - diluted (in Dollars per share)			0.01
Net (loss) income per common share - basic (in Dollars per share)	0	0	0.01
Net (loss) income per common share - diluted (in Dollars per share)	$ 0	$ 0	$ 0.01
Weighted average number of common shares outstanding:
Basic (in Shares)	111,120,000	111,120,000	111,120,000
Diluted (in Shares)	111,120,000	111,120,000	111,120,000
Cost of revenue - third parties
Revenue
Total cost of revenue	$ 484,607	$ 347,004	$ 116,146
Revenue - products sales
Revenue
Total revenue	1,069,943	1,200,541	601,570
Revenue - training
Revenue
Total revenue			154,107
Revenue - related parties
Revenue
Total revenue	$ 175,405	$ 52,943	$ 126,856

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash Flows from Operating Activities
Net (loss) income	$ (154,822)	$ (226,258)	$ 169,285
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation	135,243	407,265	56,757
Amortization	74,017	16,793
Operating lease expense	91,310	90,609	81,203
Gain on disposal of assets		(4,328)
Non-cash interest expense	17,078	17,078	33,241
Net changes in operating assets and liabilities:
(Increase) decrease in other receivables	(5,100)	2,336	(2,408)
Increase in inventories	(358,549)
Decrease (increase) in consumptive biological assets	320,821	(124,572)	(192,634)
Decrease (increase) in prepaid expenses	20,360	(27,182)
Increase in prepaid taxes	(4,633)	(103,847)	(104,788)
Increase in other current assets	(134,541)	(48,646)	(449)
Increase in accounts payable	77,007	104,608	182,849
Increase in accrued expenses	51,526	7,377	26,514
Increase in due to related parties	3,802	193,434
Increase in advance receipts	4,944
(Decrease) increase in other payable	(59,962)	89,329	131,273
(Decrease) increase in income taxes payable	(25,254)	3,629	21,530
Increase in other current liabilities	2,446	5,336
Repayment for operating lease liabilities	(91,539)	(90,955)	(80,540)
Net cash provided by (used in) operating activities from continuing operations	(35,845)	312,006	321,833
Net cash provided by operating activities from discontinued operations			37,891
Net cash provided by (used in) operating activities	(35,845)	312,006	359,724
Cash Flows from Investing Activities
Purchase of property and equipment		(349,237)	(319,487)
Proceeds from disposal of fixed asset		43,600
Net cash used in investing activities from continuing operations		(305,637)	(319,487)
Net cash used in investing activities from discontinued operations			(333)
Net cash used in investing activities		(305,637)	(319,820)
Cash Flows from Financing Activities
Proceeds from related parties			14,643
Net cash provided by financing activities from continuing operations			14,643
Net cash used in financing activities from discontinued operations			(46,851)
Net cash provided by (used in) financing activities			(32,208)
Effect of exchange rate changes on cash and cash equivalents	1,760	7,811	(692)
Net increase (decrease) in cash and cash equivalents	(34,085)	14,180	7,004
Cash and Cash Equivalents
Beginning of period	37,284	23,104	16,100
Ending of period	3,199	37,284	23,104
Less: Cash from discontinued operation
Cash from continuing operation, end of period	3,199	37,284	23,104
Supplemental Disclosure of Cash Flows
Interest	2,185	150
Income taxes		20,885
Non-cash investing and financing activities:
Recognition of lease assets and liabilities			114,712
Termination of lease assets and liabilities
Accrued liability for property and equipment		1,394,768	2,437,980
Sale of subsidiaries in exchange for debt cancellation			$ 1,152,329

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 3,199	$ 37,284
Accounts receivable		305
Consumptive biological assets		304,971
Inventories	674,196
Other receivables	5,068
Prepaid taxes	214,944	201,232
Other current assets	100,335	57,810
Total current assets	997,742	601,602
Property and equipment, net	3,632,901	3,909,599
Operating lease right-of-use assets	13,097	99,328
Other assets	13,771	13,175
Total assets	4,657,511	4,623,704
Current liabilities
Accounts payable	365,140	276,125
Accrued expenses	85,074	32,410
Income tax payable		24,006
Other payable	4,010,523	3,893,843
Advance receipts	4,912
Other current liabilities	7,892	5,226
Operating lease liabilities – current portion	13,173	87,016
Long-term loans payable – current portion	465,233	448,155
Total current liabilities	5,192,062	4,986,645
Long-term loans payable
Operating lease liabilities – noncurrent portion		12,602
Total Liabilities	5,192,062	4,999,247
Commitments and contingencies
Stockholders’ deficit
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 111,120,000 shares issued and outstanding as of December 31, 2025 and 2024	11,112	11,112
Additional paid-in capital	221,288	221,288
Accumulated deficit	(854,046)	(699,224)
Accumulated other comprehensive income	87,095	91,281
Total stockholders’ deficit	(534,551)	(375,543)
Total liabilities and stockholders’ deficit	4,657,511	4,623,704
Related party
Current liabilities
Due to related parties	$ 240,115	$ 219,864